Zobrazeno 1 - 10
of 79
pro vyhledávání: ''
Autor:
Alexey Manikhas, Hans Friedrich Koch, Charuwan Akewanlop, Kakhaber Baramidze, Sirshendu Roy, Gopichand Mamillapalli, Ashwani Marwah, Virote Sriuranpong, Eduardo Yanez Ruiz, Miguel Hernandez-Bronchud, Unmesh Gopalakrishnan, Maria Luisa T. Abesamis-Tiambeng, Guzel Mukhametshina, Abhijit Barve, Joseph D. Parra, Adolfo Fuentes-Alburo, Ihor Vynnychenko, Sarika Deodhar, Gia Nemsadze, Igor Bondarenko, Eduardo J. Pennella, Cornelius F. Waller, Hope S. Rugo, Jay Herson, Subramanian Loganathan
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2
Breast cancer research and treatment, vol 188, iss 2
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w
Publikováno v:
Breast Cancer Research and Treatment
Purpose Primary prevention of hormonally insensitive breast cancers remains an important clinical need and repurposing existing low-toxicity drugs represents a low-cost, efficient strategy for meeting this goal. This study targeted the cholesterol pa
Publikováno v:
Breast Cancer Research and Treatment. 187:31-43
Breast cancer is the most common cancer affecting women worldwide with half a million associated deaths annually. Despite a huge global effort, the pathways of breast cancer progression are not fully elucidated. Ion channels have recently emerged as
Publikováno v:
Breast Cancer Research and Treatment. 187:815-830
Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-HER
Autor:
Ralph R. Kazer, Mary Ellen Pavone, Jacqueline S. Jeruss, Molly B. Moravek, Kristin Smith, Rafael Confino, William J. Gradishar, Angela K. Lawson, Susan C. Klock
Publikováno v:
Breast Cancer Research and Treatment. 186:429-437
Breast cancer is the most common cancer in reproductive age women, and treatment can affect fertility; however, there is often concern regarding the safety of increased estradiol (E2) levels and potential delays in treatment with ovarian stimulation
Autor:
Meng Ru, Soojin Ahn, Madhu Mazumdar, Elisa R. Port, Erin Moshier, Hank Schmidt, J. Jaime Alberty-Oller, Kereeti V. Pisapati, Michael Zeidman
Publikováno v:
Breast Cancer Research and Treatment. 187:177-185
Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced HER2 + breast cancer (BC). Optimal sequencing of treatment (NAC vs. surgery first) is less clear cut in stage I (T1N0) HER2 + BC, where information from surgical pathology co
Publikováno v:
Breast Cancer Research and Treatment. 184:675-682
The primary and secondary benefits of tamoxifen as adjuvant therapy in women with hormone-receptor-positive breast cancer are substantial: a 1% decrease in the risk of death each year for 10 years with each additional year of treatment during the fir
Publikováno v:
Breast Cancer Research and Treatment. 184:699-710
Tamoxifen (TAM) resistance is a critical clinical challenge in the treatment of ERa+ breast cancer. However, the underlying mechanisms involved in TAM-resistance are not fully understood. Here we study the efficacy of UBR5 in predicting TAM-resistanc
Autor:
Maj-Britt Jensen, Lise Barlebo Ahlborn, Jens-Ole Eriksen, Signe Korsgaard Skriver, Anne Vibeke Lænkholm, Ann Knoop, Bent Ejlertsen, Maria Rossing
Publikováno v:
Breast Cancer Research and Treatment. 184:123-133
Estrogen receptor positive (ER+) breast cancer constitutes almost 85% of all breast cancer patients and are a genetically highly heterogenic group. Data on the association of somatic alterations to outcome and prognosis are however sparse. In this ne
Autor:
Debu Tripathy, Takeo Fujii, James P. Long, Sudpreeda Chainitikun, Toshiaki Iwase, Ruben Rodriguez-Bautista, Naoto T. Ueno
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Combinations of endocrine therapy (ET) and targeted therapy (CDK4/6 or mTOR inhibitors) are standard of care for HR+/HER2- metastatic breast cancer (MBC). When ET is not effective, chemotherapy is commonly used. However, clinical outcomes of